NDA 206323 · Mainpointe
Tuxarin Er
Chlorpheniramine Maleate, Codeine Phosphate · Oral
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jun 22, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
53
11 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTIAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTIAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPOID WITHDRAWAL SYNDROME See full prescribing information for complete boxed warning. TUXARIN ER exposes users to risks of...
What it is approved for
From the label in effect Jan 10, 2024.
TUXARIN ER is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. TUXARIN ER is a combination of codeine, an opioid agonist; and chlorpheniramine, a histamine-1 (H 1 ) receptor antagonist, indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. ( 1 ) Important Limitations of Use ( 1 ) Not indicated for pediatric patients under 18 years of age. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve TUXARIN ER for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Specific Population (8.4) ]. Contraindicated in pediatric patients under 12 years of age [ see Contraindications (4) , Use in Specific Populations (8.4) ]. Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) , Use in Specific Populations (8.4) ]. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ see Warnings and Precautions (5.1) ], reserve TUXARIN ER for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made.
Mechanism: Codeine Codeine is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic and antitussive properties of codeine have been speculated to come from its conversion to morphine. The precise mechanism of action of codeine and other opiates is not known; however, codeine is believed to act centrally on the cough center. In excessive doses, codeine will depress respiration. Chlorpheniramine Chlorpheniramine is a propylamine derivative antihistamine (H 1 -receptor antagonist) of the alkylamine class that also possesses...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TUXARIN ER · CHLORPHENIRAMINE MALEATE 8MG; CODEINE PHOSPHATE 54.3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Chlorpheniramine" as an intervention, any sponsor and status, largest first.
- Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.Pivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT04688736 · 6,642 participants (planned) · Start Jan 1, 2021 · Primary completion Dec 31, 2026
Drug: Placebo; Chlorpheniramine · For: Allergic Transfusion Reaction
Sites: Hefei, China; Zhoukou, China; Tai’an, China · 4 sites in all
- Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)Pivotal-lookingCompleted
Organon and CoIndustry
NCT03879772 · 679 participants · Start Mar 12, 1996 · Primary completion Jul 1, 1996
Drug: Mometasone furoate nasal spray; Beclomethasone dipropionate nasal spray and 2 more · For: Rhinitis, Allergic, Seasonal
- Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in AdultsPivotal-lookingRecruiting
Brainfarma Industria Química e Farmacêutica S/AIndustry
NCT07626437 · 620 participants (planned) · Start May 8, 2026 · Primary completion Jun 28, 2027
Drug: dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg; dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg and 1 more · For: Common Cold/Flu; Nasal Congestion; Nasal Obstruction
Sites: Belo Horizonte, Brazil; Vespasiano, Brazil; Belém, Brazil · 15 sites in all
- Effectiveness Study of Integrative Treatment for Pediatric PneumoniaPivotal-lookingCompleted
Liaoning University of Traditional Chinese MedicineAcademic, hospital or other
NCT02069665 · 451 participants · Start Dec 2011 · Primary completion Jul 2013
Drug: Xiyanping injection; Ribavirin Injection and 6 more · For: Pneumonia
Sites: Beijing, China; Guangzhou, China; Dalian, China · 6 sites in all
- Methods of T Cell Depletion Trial (MoTD)Pivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04888741 · 400 participants (planned) · Start Feb 22, 2021 · Primary completion Aug 23, 2027
Drug: Thymoglobulin; Cyclophosphamide and 3 more · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelomonocytic Leukemia and 6 more
Sites: Cardiff, United Kingdom; Birmingham, United Kingdom; Bristol, United Kingdom · 17 sites in all
- NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)Pivotal-lookingCompleted
Cancer Trials IrelandResearch network
NCT01726452 · 377 participants · Start Jan 24, 2013 · Primary completion Aug 4, 2022
Drug: Epirubicin; Cisplatin / Oxaliplatin and 7 more · For: Adenocarcinoma of the Oesophagus; Adenocarcinoma of the Oesophago-gastric Junction; Oesophageal Tumours and 2 more
Sites: Blegdamsvej 9, Denmark; Lille, France; Cork, Ireland · 29 sites in all
- Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common ColdPivotal-lookingStatus unknown
Brainfarma Industria Química e Farmacêutica S/AIndustry
NCT02735070 · 366 participants (planned) · Start Sep 2016 · Primary completion Mar 2017
Drug: Resfenol; Coristina d · For: Cold
- Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative EndoscopyStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT03940391 · 220 participants (planned) · Start May 1, 2019 · Primary completion Apr 14, 2020
Drug: Chlorpheniramine and midazolam; Midazolam · For: Endoscopy
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants.
Schifano F, Chiappini S, Miuli A, et al. · Front Psychiatry 2021 · Systematic Review
- Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis.
Mosca A, Chiappini S, Mancusi G, et al. · Curr Neuropharmacol 2025 · Systematic Review
- Effect of arginine-fluoride varnish on preventing enamel erosion by paediatric liquid medicaments.
Yip K, Abdalla MM, Bijle MN, et al. · BMC Oral Health 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines.
Robbins MS, Starling AJ, Pringsheim TM, et al. · Headache 2016 · Guideline, Systematic Review
- WITHDRAWN: Antihistamines versus aspirin for itching in late pregnancy.
Young G, Jewell D · Cochrane Database Syst Rev 2010 · Systematic Review
Sponsor: Mainpointe
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.